Prognostic factor analysis of patients with small cell lung cancer: Real-world data from 988 patients

Xiangjuan Ma | Ziran Zhang | Xiaoling Chen | Jie Zhang | Jun Nie |
Ling Da | Weiheng Hu | Guangming Tian | Di Wu | Jindi Han | Sen Han |
Jieran Long | Yang Wang | Jian Fang

INTRODUCTION

Lung cancer is the most common malignant carcinoma and the leading cause of death due to cancer both in China and in the world. Small cell lung cancer (SCLC) accounts for approximately 14% of all lung cancer cases. SCLC is divided into limited disease and extensive disease according to the staging system of Veterans Administration Lung Study Group. Systemic therapy is an essential component of appropriate treatment. Chemoradiotherapy and chemotherapy are standard therapies for limited stage (LS) SCLC and extensive stage (ES) SCLC, respectively. For decades, etoposide plus platinum (cisplatin or carboplatin) has been the most commonly used initial combination chemotherapy regimen. Until 2019, following the IMpower133 study, the addition of PD-L1-targeted immune checkpoint inhibitors to chemotherapy were recommended, with an improvement in overall survival by two months reported compared to...
chemotherapy as first-line treatment. Taking into consideration a healthy economy, accessibility to this regimen still needs to be greatly improved. In real-world clinical practice, the disease characteristics and treatment arrangement which may favor the outcomes are still something to be explored emergently. As large-scale real-world analyses are currently lacking, in this study we analyzed 1045 cases of SCLC retrospectively to explore the prognostic factors in the real-world clinical practice.

### METHODS

#### Patients and data

A total of 1045 consecutive patients presented to Peking University Cancer Hospital from August 1, 2008 to December 31, 2018 for SCLC therapies were enrolled retrospectively in this study. The inclusion criteria were histologically or cytologically-confirmed small cell lung cancer

| TABLE 1 | Characteristics of patients in the whole group, LS-SCLC and ES-SCLC subgroups |
|----------|---------------------------------------------------------------|
| Characteristic | Whole group (n = 998) | LS-SCLC (n = 481) | ES-SCLC (n = 507) |
| Total | 988 | 481 | 507 |
| Age | | | |
| Median (SD) | 59 (10.4) | 58 (10.3) | 59 (10.4) |
| <65 years | 707 (71.6%) | 360 (74.8%) | 347 (68.4%) |
| ≥65 years | 281 (28.4%) | 121 (25.2%) | 160 (31.6%) |
| Gender (%) | | | |
| Male | 760 (76.9%) | 355 (73.8%) | 405 (79.9%) |
| Female | 228 (23.1%) | 126 (26.2%) | 102 (20.1%) |
| ECOG | | | |
| 0–1 | 887 (89.8%) | 448 (93.1%) | 439 (86.6%) |
| 2–3 | 101 (10.2%) | 33 (6.9%) | 68 (13.4%) |
| First-line chemotherapy regimen | | | |
| EP/EC | 815 (82.5%) | 412 (85.7%) | 403 (79.5%) |
| Others | 173 (17.5%) | 69 (14.3%) | 104 (20.5%) |
| Response to first-line regimen | | | |
| CR/PR | 724 (73.3%) | 396 (82.3%) | 328 (64.7%) |
| SD | 152 (15.4%) | 55 (11.4%) | 97 (19.1%) |
| PD | 112 (11.3%) | 30 (6.3%) | 82 (16.2%) |
| Local irradiation | | | |
| No | 361 (36.5%) | 104 (21.6%) | 257 (50.7%) |
| Yes | 627 (63.5%) | 377 (78.4%) | 250 (49.3%) |
| Local irradiation timing | | | |
| No or passive | 521 (52.7%) | 150 (31.2%) | 368 (72.6%) |
| Initiative | 467 (47.3%) | 331 (68.8%) | 139 (27.4%) |
| Prophylactic cranial irradiation (PCI) | | | |
| No | 771 (78.0%) | 293 (60.9%) | 478 (94.3%) |
| Yes | 217 (22.0%) | 188 (39.1%) | 29 (5.7%) |
| Lines of systemic treatment | | | |
| 1–2 lines | 771 (78.0%) | 369 (76.7%) | 402 (79.3%) |
| 3 or more | 217 (22.0%) | 112 (23.3%) | 105 (20.7%) |
| Site of metastases | | | |
| Liver | - | - | 141 (27.8%) |
| Brain | - | - | 110 (21.7%) |
| Adrenal gland | - | - | 77 (15.2%) |
| Bone | - | - | 146 (28.8%) |
| Subcutaneous | - | - | 15 (3.0%) |

Abbreviations: CR, complete response; ECOG, Eastern Cooperative Oncology Group; EP/EC, etoposide and cisplatin/carboplatin; ES-SCLC, extensive stage small cell lung cancer; LS-SCLC, limited stage small cell lung cancer; PD, progressive disease; PR, partial response; SD, stable disease.
patients, who were newly diagnosed without prior treatment. Patients who received only surgery or radiotherapy were excluded. Among this cohort, 988 patients who received at least one line of systemic chemotherapy and had a record of efficacy for measurable lesions (according to RECIST) were included for further analysis.

Electronic medical records were used to obtain demographic, clinical variables and medications as follows: age, gender, stage (The Veterans Administration Lung Study Group [VALSG]), Eastern Cooperative Oncology Group (ECOG) performance status, sites of metastases, systemic therapy treatments, local therapies, efficacy, most recent follow-up, and death. Mortality data were obtained from the electronic medical records of the Follow-up System of Beijing Cancer Prevention and Research Institute. The construction of the database was conducted by an independent researcher who was not involved in the care of patients.

### Treatment

Among all 988 patients, EP/EC (etoposide and cisplatin/carboplatin) was the most often used initial chemotherapy regimen (815 patients). A total of 11 patients received etoposide only according to their physical conditions. In the early period, non EP regimens were administered according to the guidelines or clinician’s decision at that time: IP (irinotecan, cisplatin) in 52 patients, CAV (cyclophosphamide, doxorubicin, vincristine) in 39 patients, CODE (cyclophosphamide, doxorubicin, vincristine, etoposide) in 13 patients, paclitaxel plus cisplatin in 27 patients, topotecan in 17 patients, GP (gemcitabine, cisplatin) in five patients, vincristine plus etoposide in four patients, vincristine plus cisplatin in three patients, paclitaxel plus doxorubicin in one patient, and teniposide plus cisplatin in one patient.

### Table 2

| Factor                              | Univariate analysis | Multivariate analysis |
|-------------------------------------|---------------------|-----------------------|
|                                     | mOS (month) | p-value | HR      | 95% CI     | p-value |
| Gender                              |              |         | 0.822   | 0.676–1.001 | 0.051   |
| Male                                 | 15.0        | 0.017   |         |            |         |
| Female                               | 19.0        |         |         |            |         |
| Age                                 |              |         | 0.655   | 0.518–0.829 | 0.000   |
| <65-year                             | 16.5        | 0.226   |         |            |         |
| ≥65-year                             | 14.5        |         |         |            |         |
| ECOG                                |              |         | 0.445   | 0.374–0.530 | 0.000   |
| 0–1                                  | 17.0        | 0.000   |         |            |         |
| 2–3                                  | 11.0        |         |         |            |         |
| Stage at diagnosis                   |              |         | 1.038   | 0.854–1.262 | 0.707   |
| LS                                   | 24.0        | 0.000   |         |            |         |
| ES                                   | 11.0        |         |         |            |         |
| First-line chemotherapy regimen     |              |         | 1.162   | 0.932–1.448 | 0.182   |
| EP/EC                                | 17.0        | 0.023   |         |            |         |
| Others                               | 12.0        |         |         |            |         |
| Response to first-line regimen       |              |         |         |            |         |
| CR/PR                                | 20.0        | 0.000   |         |            | 0.000   |
| SD                                   | 11.0        |         | 0.325   | 0.253–0.418 |         |
| PD                                   | 7.0         |         | 0.593   | 0.446–0.788 |         |
| Local irradiation                    |              |         | 1.162   | 0.932–1.448 | 0.182   |
| No                                   | 10.0        | 0.000   |         |            |         |
| Yes                                  | 20.0        |         |         |            |         |
| Local irradiation timing             |              |         | 1.828   | 1.444–2.315 | 0.000   |
| No or passive                        | 11.0        | 0.000   |         |            |         |
| Initiative                           | 24.0        |         |         |            |         |
| Lines of systemic treatment          |              |         | 0.786   | 0.654–0.945 | 0.010   |
| 1–2 lines                            | 14.0        | 0.016   |         |            |         |
| 3 or more                            | 20.0        |         |         |            |         |

**Abbreviations:** CR, complete response; ECOG, Eastern Cooperative Oncology Group; EP/EC, etoposide and cisplatin/carboplatin; ES, extensive stage; LS, limited stage; mOS, median overall survival; PD, progressive disease; PR, partial response; SD, stable disease.
Univariate and multivariate analysis of the prognostic factors of LS-SCLC and ES-SCLC, respectively

| Factor                                | Univariate analysis | Multivariate analysis |
|----------------------------------------|---------------------|-----------------------|
|                                        | mOS (month)         | 95% CI                | p-value | HR   | 95% CI      | p-value |
| LS-SCLC                                |                     |                       |         |      |             |         |
| Gender                                 | 0.333               |                       |         | 0.749 | 0.499–1.123 | 0.167  |
| Male                                   | 23.0                | 20.2, 25.8            | 0.003   | 0.499 | 0.499–1.123 | 0.167  |
| Female                                 | 25.0                | 17.9, 32.1            | 0.747   | 0.499 | 0.499–1.123 | 0.167  |
| Age                                    | 0.747               |                       |         |      |             |         |
| <65-years                              | 25.0                | 21.6, 28.4            |         |      |             |         |
| ≥65-years                              | 23.0                | 19.5, 26.5            |         |      |             |         |
| ECOG                                   | 0.003               |                       |         | 0.749 | 0.499–1.123 | 0.167  |
| 0–1                                    | 25.0                | 22.0, 28.0            | 0.000   | 0.499 | 0.499–1.123 | 0.167  |
| 2–3                                    | 20.0                | 15.9, 24.1            | 0.472   | 0.499 | 0.499–1.123 | 0.167  |
| First-line systemic regimen            |                     |                       |         |      |             |         |
| EP/EC                                  | 25.0                | 22.5, 27.5            | 0.000   | 0.499 | 0.499–1.123 | 0.167  |
| Others                                 | 21.0                | 14.9, 27.1            | 0.000   | 0.499 | 0.499–1.123 | 0.167  |
| Response to first-line regimen         | 0.000               |                       |         |      |             |         |
| CR/PR                                  | 26.0                | 22.8, 29.2            | 0.000   | 0.499 | 0.499–1.123 | 0.167  |
| SD                                     | 15.0                | 13.0, 17.0            | 0.000   | 0.499 | 0.499–1.123 | 0.167  |
| PD                                     | 10.0                | 7.0, 13.0             | 0.053   | 0.499 | 0.499–1.123 | 0.167  |
| Local irradiation                      | 0.005               |                       |         | 0.781 | 0.539–1.313 | 0.287  |
| Yes                                    | 25.0                | 22.4, 27.6            | 0.000   | 0.539 | 0.539–1.313 | 0.287  |
| No                                     | 15.5                | 12.3, 18.7            | 0.000   | 0.539 | 0.539–1.313 | 0.287  |
| Local irradiation timing               | 0.000               |                       |         | 0.841 | 0.539–1.313 | 0.446  |
| Initiative                             | 27.0                | 23.4, 30.6            | 0.000   | 0.539 | 0.539–1.313 | 0.446  |
| No/passive                            | 15.0                | 12.4, 17.6            | 0.000   | 0.539 | 0.539–1.313 | 0.446  |
| PCI                                    | 0.000               |                       |         | 2.684 | 1.920–3.753 | 0.000  |
| No                                     | 16.0                | 14.2, 17.8            | 0.000   | 1.920 | 1.920–3.753 | 0.000  |
| Yes                                    | 39.0                | 28.5, 49.5            | 0.000   | 1.920 | 1.920–3.753 | 0.000  |
| Lines of chemotherapy                  | 0.492               |                       |         |      |             |         |
| 1–2 lines                              | 25.0                | 20.0, 30.0            | 0.492   |      |             |         |
| 3 or more                              | 23.0                | 20.9, 25.1            | 0.492   |      |             |         |
| ES-SCLC                                | 0.053               |                       |         |      |             |         |
| Gender                                 | 0.053               |                       |         |      |             |         |
| Male                                   | 11.0                | 10.2, 11.8            | 0.053   |      |             |         |
| Female                                 | 12.0                | 9.5, 14.5             | 0.053   |      |             |         |
| Age                                    | 0.237               |                       |         |      |             |         |
| <65-years                              | 12.0                | 11.3, 12.7            | 0.237   |      |             |         |
| ≥65-years                              | 11.0                | 9.9, 11.7             | 0.237   |      |             |         |
| ECOG                                   | 0.000               |                       |         | 0.671 | 0.498–0.905 | 0.009  |
| 0–1                                    | 12.0                | 11.0, 13.0            | 0.000   | 0.498 | 0.498–0.905 | 0.009  |
| 2–3                                    | 9.0                 | 6.9, 11.1             | 0.000   | 0.498 | 0.498–0.905 | 0.009  |
| First-line systemic regimen            | 0.396               |                       |         |      |             |         |
| EP/EC                                  | 11.0                | 10.3, 11.7            | 0.396   |      |             |         |
| Others                                 | 10.0                | 8.5, 11.5             | 0.396   |      |             |         |
| Response to first-line regimen         | 0.004               |                       |         |      |             |         |
| CR/PR                                  | 13.5                | 12.2, 14.8            | 0.004   |      |             |         |
| SD                                     | 9.0                 | 7.9, 10.1             | 0.004   |      |             |         |
| PD                                     | 6.0                 | 5.1, 6.9             | 0.004   |      |             |         |
Radiotherapy was the main local treatment administered to 627 patients. Only 16 patients received other local treatment such as radiofrequency ablation (12 patients), and surgery (four patients) for palliative purposes. Radiotherapy for thoracic lesions was given as 60–66 Gy (1.8 Gy daily) or 45 Gy (1.5 Gy twice daily) for LS-SCLC, while 55–60 Gy (1.8 Gy daily) was given for ES-SCLC. Patients with LS-SCLC were given concurrent thoracic radiotherapy no later than the beginning of the third cycle of chemotherapy, or sequential radiotherapy depending on performance status. After primary treatment, prophylactic cranial irradiation (PCI) was given to patients with PR/CR for primary systemic therapy when cranial magnetic resonance imaging (MRI) (contrast computed tomography [CT] when MRI could not be tolerated) revealed no brain metastases. Irradiation of other metastatic sites was dependent on the location and normal tissue constraints. Prophylactic cranial irradiation (PCI) was given to patients with PR/CR for primary systemic therapy when cranial magnetic resonance imaging (MRI) (contrast computed tomography [CT] when MRI could not be tolerated) revealed no brain metastases. Irradiation of other metastatic sites was dependent on the location and normal tissue constraints.

**Assessment of efficacy**

All patients underwent standardized evaluation. CT, MRI, positron emission tomography (PET)/CT and bone scan were employed to evaluate the efficacy and progression. An assessment was given every two cycles of systemic therapy, and every three months during the first three years of follow-up. Efficacy was evaluated as complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD).
Statistical analysis

Descriptive statistics were employed to describe the clinical characteristics of patients. Kaplan–Meier methodology was used to estimate the median overall survival (OS), whereas the differences were estimated by using Log-rank test. Factors associated with risk of death were examined by univariable analysis. The variables with a $p$-value less than 0.05 by univariable analysis were incorporated into the subsequent multivariable analysis with Cox proportional hazards model. A $p$-value less than 0.05 was defined as statistically significance. Statistical analyses were performed using SPSS version 22.0.

RESULTS

Patient characteristics and treatment

Between August 1, 2008 and December 31, 2018, a total of 988 patients were legally confirmed to be eligible for analysis in the study. At the time of data cutoff, the median follow-up was 10.0 months (interquartile range 7–19 months). A total of 603 patients (60.3%) had died. Median age was 59.0 years (range: 16–83), and 281 patients (28.4%) were 65 years old or above. A total of 481 (48.7%) patients initially presented with limited stage disease, while 507 (51.3%) patients had extensive stage disease at diagnosis. A total of 89.8% (887) of the patients had good performance status at the beginning of treatment. For the subgroups of LS and ES disease, there were more male, older patients and more patients of ECOG 2–3 in the ES subgroup. A total of 32.9% of patients with ES-SCLC had multiple extra-thoracic organ metastases at diagnosis. The top three common metastatic organs were bone (28.8%), liver (27.8%) and brain (21.7%).

A total of 815 (82.5%) patients received EP as first-line systemic treatment, while 173 (17.5%) patients had other systemic chemotherapy regimens. There were more patients with LS-SCLC (85.7%) who accepted EP/EC as first-line chemotherapy. In total, 73.3% of patients achieved a CR/PR for the first systemic regimen, 15.4% of SD and 11.3% of PD. More patients with LS-SCLC achieved CR/PR (82.3% vs. 64.7%) whereas more patients with ES-SCLC (16.2% vs. 6.3%) had progression on first-line chemotherapy. A total of 771 (78.0%) patients received no more than two lines of systemic therapy, and 217 (22.0%) had three or more lines. A total of 67.1% of the patients had local treatments during the course of disease, and most (625/663) had received irradiation. Initiative irradiation was defined as concurrent thoracic irradiation or sequential irradiation depending on the tolerance of patients with LS-SCLC, or thoracic radiotherapy for patients with ES-SCLC who had responded to primary systemic therapy and selective radiotherapy for stable or slowly progressing, asymptomatic metastases conditions; conversely, limited-term radiotherapy for rapidly progressing, symptomatic lesions was defined as passive irradiation. In total, 467 (47.3%) patients received initiative radiotherapy, while 160 (16.2%) patients had passive radiotherapy and 360 (36.5%) patients had no radiotherapy. There was a higher ratio of patients who received local irradiation (78.4% vs. 49.3%) in LS-SCLC compared with ES-SCLC, and many more patients (331/68.8% vs. 139/27.4%) received initiative radiotherapy in LS-SCLC. In total, 22.0% of patients accepted PCI, and 39.1% of patients with LS-SCLC while 5.7% of ES-SCLC. The demographic characteristics and treatments of the whole group are shown in Table 1.

Survival and prognosis factors

The median overall survival (OS) of the whole group was 16.0 months. Univariate and multivariate analysis revealed that limited-stage, good performance score (PS) Eastern
**FIGURE 2** Survival curves of patients with extensive stage small cell lung cancer (ES-SCLC) (Log-rank test). (a) Performance status (PS) Eastern Oncology Cooperative Group (ECOG) before treatment 0–1 versus 2–3 ($p = 0.009$). (b) Responses to first-line systemic therapy. CR/PR, complete response/partial response; SD, stable disease; PD, progressive disease ($p < 0.001$). (c) Initiative irradiation versus passive irradiation or no irradiation ($p = 0.004$). (d) Systemic therapy lines: 1–2 lines versus 3 or more ($p < 0.001$). (e) Liver metastases versus no liver metastases ($p = 0.016$). (f) Bone metastases versus no bone metastases ($p = 0.022$). (g) Subcutaneous metastases versus no subcutaneous metastases ($p = 0.028$)
Cooperative Oncology Group (ECOG: 0–1), response to first-line systemic treatment (CR/PR), receiving initiative irradiation and more lines of chemotherapy (three or more lines) were independent prognostic factors for OS (Table 2).

Patients with LS-SCLC had a median OS of 24.0 months, the one-, two-, and five-year overall survival rates were 78.7%, 48.8% and 24.2%, whereas the median OS of patients with ES-SCLC was just 11.0 months, and one-, two-, and five-year overall survival rates were 41.6%, 14.4% and 4.3%. In the LS-SCLC subgroup, only response to first-line systemic therapy and PCI were revealed by multivariate analysis to be related to survival.

For patients with ES disease, multivariate analysis revealed good PS (ECOG 0–1), response to first-line therapy, initiative local irradiation, and three or more lines of systemic therapy were associated with a more favorable prognosis, while liver, bone, or subcutaneous metastases predicted worse survival (Table 3).

In the LS-SCLC subgroup, patients who received a CR/PR to first systemic therapy had a median OS of 26.0 months, whereas it was 15.0 months for SD and only 10 months for PD. The median survival of patients receiving PCI and not receiving PCI were 39.0 months and 16.0 months, respectively (Figure 1).

In the ES-SCLC subgroup, median OS of patients who achieved CR/PR was 13.5 months compared with 9.0 months of SD and 6.0 months with PD. Patients who accepted initiative irradiation therapy had a superior median survival (19.0 vs. 9.0 months). Having three or more lines of systemic therapy was related to better survival (15.0 vs. 10.0 months). Good PS (12.0 vs. 9.0 months), no metastasis of the liver (12.0 vs. 9.0 months), bone (12.0 vs. 9.0 months) or subcutaneous condition (11.0 vs. 8.0 months) at diagnosis provided survival benefits in those patients (Figure 2).

**DISCUSSION**

SCLC is characterized by rapid progression and widespread metastases. In addition to epidemiological characters such as performance status, stage and metastases, treatment arrangements also have great impacts on overall survival. Systemic therapy is an essential component of appropriate treatment. Thoracic radiotherapy is recommended for patients with LS-SCLC with the goal being to achieve a cure; for selected patients with ES-SCLC, radiotherapy is recommended to palliate symptoms. However, some studies have reported that more aggressive radiotherapy improved survival of selected patients with ES-SCLC.8, 9

As far as we know, this study may be one of the largest studies of SCLC from a single center. The real-world data from 988 patients confirmed that stage is still one of the most important prognostic factors for survival. The performance status (ECOG) at diagnosis was confirmed to be the characteristic related with survival, especially in the ES group. Different from previous studies,10 gender or age were not involved with prognosis in this group. Compared to no or single metastases, multiple metastases outside the thoracic region is an unfavorable factor for survival as previously reported.11 In this study, the presence of liver metastases was shown to predict a worse prognosis in the ES-SCLC group,12–14 as well as bone metastases at diagnosis. Our data first revealed that subcutaneous metastasis at diagnosis is an independent risk factor for survival in ES-SCLC and may predict the shortest median OS of only eight months compared with other distant metastases. Subcutaneous metastasis is uncommon at diagnosis, and is therefore rarely described in previous studies.

Beyond the characteristics at diagnosis, treatment arrangement played a more crucial role in overall survival. A systematic analysis performed by Taofeek et al.15 showed the survival for patients with refractory SCLC and sensitive SCLC were definitely different (5.4 months vs. 7.7 months). A retrospective analysis of 207 patients revealed response to chemotherapy was the most important prognostic factor over disease characteristics at diagnosis.16 Another study included 407 Chinese patients, and showed that the patients who achieved CR/PR to initial therapy had a superior OS of 8.3 months for LS-SCLC and 7.8 months for ES-SCLC than those who achieved SD/PD.17 In our study, patients who received a response to first-line chemotherapy with CR/PR, SD and PD had a different median OS of 26.0, 15.0 and 10.0 months in the LS-SCLC group (p < 0.05), whereas it was 13.5, 9.0 and 6.0 months in the ES-SCLC group (p < 0.05). Response to primary systemic therapy is one of the independent prognosis factors for both LS-SCLC and ES-SCLC proven by multivariate analysis.

Initiative radiotherapy in LS-SCLC included concurrent thoracic irradiation or sequential irradiation and depended on tolerance in this study. Patients who accepted initiative radiotherapy had a prolonged OS of almost double those who did not (27.0 months vs. 15.0 months). Perhaps due to consistency of initial treatment and the relatively high ratio (68.8%) of initiative radiotherapy in this group, only PCI was the independent prognosis factor for survival in multivariate analysis, but not initiative radiotherapy. Although PCI was only performed in 39.1% patients, those who received PCI had a much longer survival of 39.0 months (vs. 16.0 months) than reported in this group.18

In contrast to its established role in LS-SCLC, the results of radiation therapy as an important part of the treatment regimen for OS are conflicting. The pivotal study of Jeremic et al. showed patients in ES-SCLC with good performance (PS 0), achieved PR/CR at local (intrathoracic) and CR at the distant level (metastases) from three cycles of initial chemotherapy, and achieved survival benefits from thoracic radiation therapy followed by PCI.19 Data of 260 patients excluded intracranial and pleural metastasis with ES-SCLC from a randomized CREST trial, showed low dose thoracic radiotherapy (30 Gy in 10 fractions) after first-line chemotherapy (six cycles) improved progression-free survival (PFS) but did not meet the primary endpoint of OS.9, 20 The results were conflicting, but the large gap between the two
studies in patient characteristics and treatment aspects should not be ignored. The Radiation Therapy Oncology Group study 0937 compared radiation therapy to the thorax and metastases following PCI and PCI in ES-SCLC patients. After achieving a response to initial chemotherapy, the study was closed prior to meeting its accrual target as it crossed the futility boundary for OS.\textsuperscript{21} ES-SCLC is such a widespread disease and the sites of failure after initial chemotherapy are likely to be the sites of presenting disease, and radiation therapy in these sites may alter the failure patterns. Instead of focusing on thoracic radiation therapy or radiotherapy to sites of metastases, we analyzed the impact of initiating radiotherapy for ES-SCLC in our study. Initiative radiotherapy for ES-SCLC in this study included not only higher dose thoracic radiotherapy after response to primary chemotherapy, but also aggressive radiotherapy for stable or slowly progressing, asymptomatic metastatic sites outside the thoracic region. A total of 139 patients (27.4% of 507 cases) accepted initiating irradiation therapy and achieved much higher OS (19.0 vs. 9.0 months). Consolidation radiotherapy with chemotherapy in this study, other than the benefits of PFS as reported,\textsuperscript{22} improved OS in ES-SCLC, and may potentially be involved with changing the pattern of recurrence.

Another independent prognostic factor for survival in addition to a response to primary chemotherapy and initiation irradiation, is patients who receive three or more lines of systemic therapy. More opportunities for systemic therapy provide greater patient survival benefits. A retrospective analysis of 202 SCLC patients showed good PS, and a longer period to treatment failure after second-line chemotherapy were favorable prognostic factors for those patients who had received third-line chemotherapy.\textsuperscript{23} Irrespective of this, all the above mentioned data suggests that a more aggressive strategy of systemic therapy, especially combined with initiation radiotherapy, provides survival benefits for patients with ES-SCLC.

Although data from one center means consistency of principles for treatment selection, this is also one of the limitations of the present study. However, this study involved a relatively large number of patients both with LS-SCLC and ES-SCLC. Real-world data showed the proportion of patients receiving PCI was still low in LS-SCLC although that evidence might not influence our conclusions. Recently, whether to give PCI to patients with ES-SCLC has been controversial. Data from the present study is so small that it possibly affects the results.

Real-world data demonstrates in addition to PS and metastatic sites, response to primary systemic treatment and PCI for LS-SCLC, and initiative irradiation of original and metastatic sites for ES-SCLC was found to improve overall patient survival. A more aggressive treatment strategy for SCLC, especially for ES-SCLC, initiative radiotherapy and more lines of systemic therapy provided survival benefits. The results indicate that further studies, especially well-controlled prospective studies, focusing on local treatment combined with systemic therapy in ES-SCLC, are urgently required.

CONFLICT OF INTEREST
No authors report any conflict of interest.

ORCID
Xiangjuan Ma https://orcid.org/0000-0002-1118-3725

REFERENCES
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBCAN 2012. Int J Cancer. 2015;136: E359–86.
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.
3. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24:4539–44.
4. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep. 1973:431–42.
5. Simon GR, Turrissi A. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007; 132:324s–39s.
6. Fruh M, De Ruyscher D, Popat S, Cinó L, Peters S, Felip E, et al. Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6): vi99–vi105.
7. Horn L, Mansfield AS, Szczesna A, Havel L, Krazakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379: 2220–9.
8. Wu D, Fang J, Nie J, Dai L, Chen X, Zhang J, et al. Effects of local radiation combined with chemotherapy in the treatment of patients with extensive-stage small cell lung cancer. Chin J Lung Cancer. 2015;18(5): 272–9.
9. Slotman BJ, Faire-Kinn C, van Tinteren H, Keijser A, Praag J, Kneijens J, et al. Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: a secondary analysis of the phase III CREST trial. Lung Cancer. 2017;108:150–3.
10. Foster NR, Mandrekar SJ, Schild SE, Nelson GD, Rowland KM Jr, Deming RL, et al. Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group (NCCTG) trials. Cancer. 2009;115:2721–31.
11. Albain KS, Crowley JJ, LeBlanc M, Linton RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patients Southwest Oncology Group database. J Clin Oncol. 1990;8:1563–74.
12. Ren Y, Dai C, Zheng H, Zhou F, She Y, Jiang G, et al. Prognostic effect of liver metastasis in lung cancer patients with distant metastasis. Oncotarget. 2016;7(33):53245.
13. Nakazawa K, Kurishima K, Tamura T, Kagohashi K, Ishikawa H, Satoh H, et al. Specific organ metastases and survival in small cell lung cancer. Oncol Lett. 2012;4:617–20.
14. Rühimaki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, et al. Metastatic sites and survival in lung cancer. Lung Cancer. 2014;86:78–84.
15. Owonikoko TK, Behera M, Chen Z, Bhimani C, Curran WJ, Khuri FR, et al. A systematic analysis of efficacy of second line chemotherapy in sensitive and refractory small cell lung cancer. J Thorac Oncol. 2012;7(5):866–72.
16. Tas FF, Aydiner A, Topuz E, Camlica H, Saip P, Eralp Y. Factors influencing the distribution of metastases and survival in extensive disease small cell lung cancer. Anta Oncol. 1999;38:1011–5.
17. Hong X, Xu Q, Yang Z, Wang M, Yang F, Gao Y, et al. The value of prognostic factors in Chinese patients with small cell lung cancer: a retrospective study of 999 patients. Clin Respir J. 2018;12:433–47.
18. Ezc C, Roengvoraphoj O, Niyazi M, Hildebrandt G, Fietkau R, Belka C, et al. Treatment response and prophylactic cranial irradiation are prognostic factors in a real-life limited-disease small-cell lung cancer patient cohort comprehensively staged with cranial magnetic resonance imaging. Clin Lung Cancer. 2017;18:e243–9.
19. Jeremic B, Shibamoto Y, Nikolic N, Milicic B, Milisavljevic S, Dagovic A, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small cell lung cancer: a randomized study. J Clin Oncol. 1999;17:2092–9.
20. Slotman BJ, van Faivre-Finn C, Praag JO, Knegjens JL, El Sharouni SY, Hatton M, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385:36–42.
21. Gore EM, Hu C, Sun AY, Grimm DF, Ramalingam SS, Dunlap NE, et al. Randomized phase II study comparing prophylactic cranial irradiation alone to prophylactic cranial irradiation and consolidative extra-cranial irradiation for extensive disease small cell lung cancer (ED-SCLC) NRG oncology RTOG 0937. J Thorac Oncol. 2017;12(10):1561–70.
22. Yee D, Butts C, Rimn A, Joy A, Smylie M, Fenton D, et al. Clinical trial of post-chemotherapy consolidation thoracic radiotherapy for extensive-stage small cell lung cancer. Radiother Oncol. 2012;102:234–8.
23. Saruwatari K, Umemura S, Nomura S, Kirita K, Matsumoto S, Yoh K, et al. Prognostic factor analysis in patients with small-cell lung cancer treated with third-line chemotherapy. Clin Lung Cancer. 2016;17:581–587.

How to cite this article: Ma X, Zhang Z, Chen X, et al. Prognostic factor analysis of patients with small cell lung cancer: Real-world data from 988 patients. Thoracic Cancer. 2021;12:1841–1850. https://doi.org/10.1111/1759-7714.13846